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Abstract 
Background: Representative data on the secular trends in cardiovascular disease (CVD) are limited in Asian popula‑
tions with diabetes. We aimed to estimate the temporal trends in cardiovascular complications using Korean nation‑
wide whole population‑based claims data in subjects with and without diabetes.
Methods: Type 2 diabetes was defined as a current medication history of anti‑diabetic drugs and the presence of 
International Classification of Diseases (ICD)‑10 codes (E11–E14) as diagnosis. We compared the 8‑year rates of six 
cardiovascular complications [i.e., ischemic heart disease, acute myocardial infarction (AMI), ischemic stroke, hemor‑
rhagic stroke, percutaneous coronary intervention (PCI), and coronary artery bypass graft (CABG)] in Korean adults 
aged 30 years and older using data from four consecutive nationwide databases (2006–2007, 2008–2009, 2010–2011, 
and 2012–2013) of Korean national health insurance service.
Results: A total of 1,645,348, 1,971,559, 2,291,247, and 2,562,612 subjects with type 2 diabetes were found in the 
year of 2006–2007, 2008–2009, 2010–2011, and 2012–2013, respectively. Age and gender standardized rates of the 
six predefined cardiovascular complications decreased in Korean adults with type 2 diabetes during the study period. 
The greatest relative reductions were observed for hospitalization due to AMI (−37.28%), followed by hospitalizations 
due to ischemic stroke (−36.98%). In the overall population without type 2 diabetes, the greatest relative reductions 
were observed for hospitalization for hemorrhagic stroke (−29.47%), followed by hospitalization due to ischemic 
stroke (−28.92%). Relative decreases in all six predefined cardiovascular complications were generally more profound 
in adults with diabetes than in those without diabetes, which led to significant decrease in the relative risks of all six 
cardiovascular complications in subjects with diabetes over the past 8 years. However, people with diabetes still had a 
two‑ to sixfold higher risk of hospitalization for major CVD events and interventions than people without diabetes.
Conclusions: Our findings suggest a significant reduction in the rate of people affected by CVD within the diabetic 
population. However, as the number of people with diabetes rises, the absolute burden of CVD will still be high in 
Korea.
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Background
Diabetes is one of the most common metabolic disor-
ders in the world and its prevalence in adults has been 
increasing in recent decades [1]. It has been estimated 
that the number of people in the United States with diag-
nosed diabetes will increase by 165% from 2000 to 2050, 
from 11 million to 29 million [2]. However, there are 
considerable variations in the burden of diabetes across 
regions, with developing countries disproportionately 
affected [1].
Diabetes is a well-known risk factor for cardiovascular 
disease (CVD) and is associated with a two- to fourfold 
increase in the risk of coronary artery disease devel-
opment [3–5]. Fortunately, intensive glycemic control 
implemented in the early stage of diabetes as well as mul-
tifactorial risk management that includes better control 
of high blood pressure and dyslipidemia show beneficial 
effects on macrovascular complications and related mor-
tality in subjects with diabetes [6, 7]. These studies were 
followed by a steady improvement in diabetes care and 
risk factor control [8–10]. Indeed, recent studies have 
reported decreases in cardiovascular complications in 
patients with diabetes, which have been attributed to 
better risk factor management [11–14]. For instance, 
Booth et al. [13] demonstrated a significant reduction in 
the rate of people affected by CVD within the diabetic 
population using provincial health claims data between 
1992 and 2000. More recently, Gregg et al. [11], showed 
that the rates of diabetes-related complications declined 
substantially between 1990 and 2010, with the largest 
relative decline in acute myocardial infarction (AMI). 
However, most studies have been conducted in Western 
populations.
Representative data on the secular trends of diabetes-
related cardiovascular complications are limited in Asian 
populations, particularly in Korea, where striking ethnic 
differences in CVD risk might exist [15], and diabetes is 
a major health problem with a rapidly increasing preva-
lence—from 1.5 to 9.9%—over the past 40 years [16]. The 
last decade has shown tremendous advances in the treat-
ment of heart disease and CVD risk factors in Korea [17], 
as in Western countries [13, 18, 19].
Despite these improvements, it remains unclear 
whether cardiovascular complications have uniformly 
decreased among Korean populations with diabetes. 
Therefore, the aim of our present study was to estimate 
the temporal trends in major cardiovascular complica-
tions requiring hospital admission and cardiovascular 
interventions in Korean people with and without diabetes 
using nationwide whole population-based claims data. 
We also aimed to estimate the relative risk of these events 
in people with diabetes.
Methods
Data sources
A national health insurance system was initiated in 
1963 in South Korea in response to the National Health 
Insurance Act, which mandated the participation of all 
citizens. Currently, the national health insurance service 
(NHIS) maintains and manages all databases of health 
service utilization in Korea. Briefly, the NHIS in Korea 
is a single-payer organization that is mandatory for all 
residents in Korea. Because it has adopted a fee-for-
service model to pay health care providers who treat or 
examine Korean patients, NHIS obtains information on 
patient demographics, medical use/transaction informa-
tion, insurers’ payment coverage, and patients’ deduction 
and claims databases (diagnosis, prescription, and/or 
consultation statements). Therefore, the NHIS database 
represents the entire Korean population and can be used 
as a population-based database. Further details of this 
database have been described previously [20, 21]. The 
National Health Insurance Sharing Service manages the 
NHIS database by operating three organizations within 
the “Big Data Steering Department” to maintain the 
quality of the database such as the “Information Analy-
sis Division”, the “Data Convergence Division” and the 
“Information Analysis Division” [22].
In the present analysis, retrospective data of individuals 
older than 30 years of age were extracted from the Korean 
NHIS database between January 2006 and December 
2013. The NHIS provides data without individual identi-
fiers, in accordance with the Act on the Protection of Per-
sonal Information Maintained by Public Agencies. Thus, 
the database included an unidentifiable code represent-
ing each individual. Because this study was based on data 
from the NHIS, informed consent was not specifically 
obtained from the individuals. This study was approved 
by the Korean National Institute for Bioethics for Bioeth-
ics Policy (P01-201504-21-005).
Definition of type 2 diabetes
Considering the characteristics of the NHIS database, 
an operational definition of diabetes was applied to the 
analysis. In this present study, individuals were defined as 
having diabetes if anti-diabetic drugs (insulins, sulfonylu-
reas, metformin, meglitinides, thiazolidinediones, dipep-
tidyl peptidase-4 inhibitors, and α-glucosidase inhibitors) 
Keywords: Type 2 diabetes, National, Cardiovascular disease, Complications, Trend
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were prescribed with the presence of the International 
Classification of Diseases, 10th revision (ICD-10) codes 
E11 (non-insulin-dependent diabetes mellitus), E12 (mal-
nutrition-related diabetes mellitus), E13 (other specified 
diabetes mellitus), or E14 (unspecified diabetes mellitus), 
as either principal diagnosis or additional diagnosis [20].
Definition of cardiovascular complications
We identified incident cases of six diabetes-related car-
diovascular complications: ischemic heart disease, AMI, 
ischemic stroke, hemorrhagic stroke, percutaneous coro-
nary intervention (PCI), and coronary artery bypass graft 
(CABG). To identify cases of ischemic heart disease, 
AMI, ischemic stroke, and hemorrhagic stroke, we used 
the hospital discharge records based on ICD-10 codes 
as a principal diagnosis. The specific codes used were as 
follows: for ischemic heart disease, ICD-10 codes of I20 
(angina pectoris), I21 (ST elevation and non-ST eleva-
tion myocardial infarction), I22 (subsequent ST eleva-
tion and non-ST elevation myocardial infarction), I23 
(certain current complications following ST elevation 
and non-ST elevation myocardial infarction), I24 (other 
acute ischemic heart diseases), and I25 (chronic ischemic 
heart disease); for AMI, ICD-10 codes of I21, I22, and 
I23; for ischemic stroke, ICD-10 codes of I63 (cerebral 
infarction), I64 (stroke, not specified as hemorrhage or 
infarction), I693 (sequelae of cerebral infarction), I694 
(sequelae of stroke, not specified as hemorrhage or 
infarction), and G45 (transient cerebral ischemic attacks 
and related syndromes); and for hemorrhagic stroke, 
ICD-10 codes of I60 (subarachnoid hemorrhage), I61 
(intracerebral hemorrhage), I62 (other nontraumatic 
intracranial hemorrhage), I690 (sequelae of subarach-
noid hemorrhage), I691 (sequelae of intracerebral hem-
orrhage), and I692 (sequelae of nontraumatic intracranial 
hemorrhage). We ascertained the incident cases of PCI 
and CABG by identifying the procedure codes of PCI 
(M6551-2, M6561-4, and M6571-2) and CABG (O1641-
2, O6147, OA641-2, and OA647) [23]. We excluded any 
patients with a history of the six defined diabetes-related 
cardiovascular complications between 2002 and 2005.
To investigate possible explanations for the changing 
patterns of the six cardiovascular complications in sub-
jects with or without type 2 diabetes, we analyzed the 
trends of hypertension and dyslipidemia, the two most 
representative risk factors for cardiovascular complica-
tions [24]. Individuals were defined as having hyperten-
sion if anti-hypertensive medications were prescribed 
with the presence of the ICD-10 codes I10 (essential 
hypertension), I11 (hypertensive heart disease), I12 
(hypertensive renal disease), I13 (hypertensive heart and 
renal disease) or I15 (secondary hypertension). Similarly, 
individuals were defined as having dyslipidemia if lipid 
lowering agents were prescribed with the presence of the 
ICD-10 codes E78 (disorders or lipoprotein metabolism 
and other lipidemias).
Statistical analysis
All rates are expressed as the number of events per 
10,000 persons per year and the 95% confidence interval 
(CI), with age and gender standardized to Korean Cen-
sus data for the year 2010 and the use of six age groups: 
30–39  years, 40–49  years, 50–59  years, 60–69  years, 
70–79  years and 80  years or more. Changes in cardio-
vascular complications between 2006 and 2013 were 
presented as percent change. Because the claims can be 
made in the month after the actual admission for CVD 
and the procedures for PCI and CABG, we calculated the 
number of events within a two years period (i.e., 2006 
and 2007, 2008 and 2009, 2010 and 2011, and 2012 and 
2013). We used the generalized linear model to test for 
linear trends of each cardiovascular complication over 
time. We estimated the relative risk (RR) and 95% CI of 
each cardiovascular complication in diabetic populations 
compared with those without diabetes using Poisson 
regression. Statistical analyses were performed using SAS 




A total of 1,645,348, 1,971,559, 2,291,247, and 2,562,612 
subjects with type 2 diabetes were found in the year of 
2006–2007, 2008–2009, 2010–2011, and 2012–2013, 
respectively. The prevalence of type 2 diabetes increased 
from 5.6% in the year of 2006–2007 to 7.7% in the year of 
2012–2013. The distribution of study participants from 
2006 to 2013 by gender and age group (i.e., aged <65 years 
and ≥65 years) is indicated in Additional file 1: Table S1.
Rates of cardiovascular complications according to the 
status of diabetes
As shown in Tables 1, 2, 3, 4, 5 and 6, the age and gender 
standardized rates of six predefined cardiovascular com-
plications decreased in Korean adults with type 2 dia-
betes during the study period. In the overall population 
with type 2 diabetes, the greatest absolute reduction was 
in the number of hospitalizations due to ischemic heart 
disease (−108.45 fewer cases per 10,000 persons, Table 1; 
Fig.  1a), followed by hospitalizations due to ischemic 
stroke (−69.87 fewer cases per 10,000 persons, Table  3; 
Fig.  1a), AMI (−32.47 fewer cases per 10,000 persons, 
Table  2; Fig.  1a), hemorrhagic stroke (−20.01 fewer 
cases per 10,000 persons, Table  4; Fig.  1a), PCI (−2.59 
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fewer cases per 10,000 persons, Table  5; Fig.  1a), and 
CABG (−2.56 fewer cases per 10,000 persons, Table  6; 
Fig.  1a), respectively. When expressed in terms of the 
absolute number of cases (i.e., irrespective of changes in 
population size), the numbers of hospitalizations due to 
ischemic heart disease, AMI, ischemic stroke, hemor-
rhagic stroke, PCI, and CABG increased by 9879 cases, 
876 cases, 847 cases, and 1623 cases, 9932 cases, and 194 
cases respectively, from 2006 to 2013 (data not shown).
In the overall population with type 2 diabetes, the 
greatest relative reductions observed were for hospitali-
zation due to AMI (−37.28%, Table 2), followed by hos-
pitalizations due to ischemic stroke (−36.98%, Table  3). 
When we performed subgroup analyses according to 
Table 1 Age and gender standardized rates of ischemic heart disease among Korean adults according to the presence or 
absence of diabetes (2006–2013)
In the whole analysis, P values for interaction between diabetes status and years was less than .0001 by regression models
Variables Year Change P value
2006–2007 2008–2009 2010–2011 2012–2013 Absolute change Percent change Linear trend
Ischemic heart disease
 Overall population
  No. of events/10,000 in 
diabetes
368.02 338.28 289.65 259.57 −108.45 −29.47 <.0001
  95% CI 360.53–375.51 331.81–344.75 284.36–294.95 254.74–264.41
  No. of events/10,000 in 
non‑diabetes
117.44 115.74 106.79 100.23 −17.21 −14.65 <.0001
  95% CI 117.34–117.54 115.65–115.83 106.72–106.87 100.16–100.30
  RR (95% CI) 3.13 (3.10–3.17) 2.92 (2.89–2.95) 2.71 (2.68–2.74) 2.59 (2.56–2.62) <.0001
 Men
  No. of events/10,000 in 
diabetes
376.91 351.86 307.31 276.17 −100.74 −26.73 <.0001
  95% CI 364.49–389.33 340.89–362.82 298.38–316.23 268.04–284.31
  No. of events/10,000 in 
non‑diabetes
120.53 119.2 111.25 104.91 −15.62 −12.96 <.0001
  95% CI 120.31–120.74 119.01–119.39 111.08–111.41 104.77–105.06
  RR (95% CI) 3.13 (3.09–3.16) 2.95 (2.92–2.98) 2.76 (2.73–2.79) 2.63 (2.61–2.66) <.0001
 Women
  No. of events/10,000 in 
diabetes
359.75 325.64 273.22 244.12 −115.63 −32.14 <.0001
  95% CI 342.59–376.90 311.01–340.27 261.22–285.21 233.15–255.10
  No. of events/10,000 in 
non‑diabetes
114.57 112.51 102.65 95.87 −18.7 −16.32 <.0001
  95% CI 114.38–114.76 112.34–112.68 102.50–102.80 95.74–95.99
  RR (95% CI) 3.14 (3.11–3.17) 2.89 (2.86–2.93) 2.66 (2.63–2.69) 2.55 (2.52–2.57) <.0001
 Aged < 65 years
  No. of events/10,000 in 
diabetes
280.04 262.22 226.39 205.71 −74.33 −26.54 <.0001
  95% CI 268.84–291.24 252.26–272.19 218.48–234.30 198.49–212.92
  No. of events/10,000 in 
non‑diabetes
65.41 65.27 61.08 58.66 −6.75 −10.32 <.0001
  95% CI 65.35–65.48 65.22–65.33 61.03–61.13 58.62–58.71
  RR (95% CI) 4.28 (4.23–4.33) 4.02 (3.97–4.06) 3.71 (3.67–3.75) 3.51 (3.47–3.55) <.0001
 Aged ≥ 65 years
  No. of events/10,000 in 
diabetes
820.52 732.68 617.92 534.07 −286.45 −34.91 <.0001
  95% CI 755.38–885.67 690.16–775.2 590.45–645.4 515.73–552.41
 No. of events/10,000 in 
non‑diabetes
404.83 402.36 372.02 340.52 −64.31 −15.89 <.0001
 95% CI 401.01–408.65 398.89–405.82 369.09–374.96 338.15–342.89
 RR (95% CI) 2.03 (2.01–2.05) 1.82 (1.8–1.84) 1.66 (1.64–1.68) 1.57 (1.55–1.58) <.0001
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gender and age group (i.e., aged <65 years and ≥65 years) 
in Korean adults with type 2 diabetes, both genders 
showed similar patterns in the relative reductions, in 
which the greatest relative reduction were observed in 
following order; hospitalization due to AMI and ischemic 
stroke (−34.52 and −33.67% for men and −40.78 and 
−40.05% for women, as shown in Table  2 for AMI and 
Table 3 for ischemic stroke, respectively).
For adults with type 2 diabetes aged  <65  years, the 
greatest relative reductions were observed for AMI 
(−35.84%, Table  2), followed by CABG (−32.67%, 
Table 6). For adults with type 2 diabetes aged ≥65 years, 
Table 2 Age and gender standardized rates of AMI among Korean adults according to the presence or absence of diabe-
tes (2006–2013)
In the whole analysis, P values for interaction between diabetes status and years was less than .0001 by regression models
Variables Year Change P value
2006–2007 2008–2009 2010–2011 2012–2013 Absolute change Percent change Linear trend
AMI
 Overall population
  No. of events/10,000 in 
diabetes
87.09 81.36 61.67 54.62 −32.47 −37.28 <.0001
  95% CI 85.27–88.91 79.82–82.89 60.64–62.69 53.71–55.54
  No. of events/10,000 in 
non‑diabetes
26.31 26.15 21.43 19.59 −17.21 −25.50 <.0001
  95% CI 26.29–26.33 26.13–26.17 21.42–21.45 19.57–19.60
  RR (95% CI) 3.31 (3.24–3.38) 3.11 (3.05–3.18) 2.88 (2.82–2.94) 2.79 (2.73–2.85) <.0001
 Men
  No. of events/10,000 in 
diabetes
100.97 92.90 73.55 66.12 −34.85 −34.52 <.0001
  95% CI 97.37–104.58 89.84–95.95 71.34–75.77 64.16–68.08
  No. of events/10,000 in 
non‑diabetes
30.34 29.51 24.13 22.27 −8.07 −26.60 <.0001
  95% CI 30.29–30.39 29.46–29.56 24.09–24.16 22.24–22.30
  RR (95% CI) 3.33 (3.26–3.4) 3.15 (3.08–3.21) 3.05 (2.98–3.11) 2.97 (2.91–3.03) <.0001
 Women
  No. of events/10,000 in 
diabetes
74.17 70.61 50.60 43.92 −30.25 −40.78 <.0001
  95% CI 70.52–77.81 67.52–73.69 48.69–52.51 42.21–45.62
  No. of events/10,000 in 
non‑diabetes
22.55 23.01 18.92 17.09 −5.46 −24.21 <.0001
  95% CI 22.52–22.59 22.98–23.05 18.89–18.95 17.07–17.11
  RR (95% CI) 3.29 (3.21–3.37) 3.07 (3.00–3.14) 2.67 (2.61–2.74) 2.57 (2.51–2.63) <.0001
 Aged < 65 years
  No. of events/10,000 in 
diabetes
66.35 63.53 47.05 42.57 −23.78 −35.84 <.0001
  95% CI 63.62–69.08 61.09–65.98 45.57–48.52 41.20–43.93
  No. of events/10,000 in 
non‑diabetes
14.12 14.25 11.63 10.70 −3.42 −24.22 <.0001
  95% CI 14.11–14.13 14.24–14.27 11.62–11.64 10.69–10.71
  RR (95% CI) 4.70 (4.59–4.81) 4.46 (4.36–4.56) 4.05 (3.95–4.15) 3.98 (3.88–4.08) <.0001
 Aged ≥ 65 years
  No. of events/10,000 in 
diabetes
202.04 186.77 145.69 122.44 −79.60 −39.40 <.0001
  95% CI 185.21–218.87 175.20–198.33 138.61–152.77 118.07–126.81
  No. of events/10,000 in 
non‑diabetes
100.86 101.48 84.69 75.72 −25.14 −24.93 <.0001
  95% CI 99.83–101.88 100.54–102.41 83.98–85.41 75.17–76.28
  RR (95% CI) 2.00 (1.96–2.05) 1.84 (1.8–1.88) 1.72 (1.68–1.76) 1.62 (1.58–1.65) <.0001
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the hospitalization due to ischemic stroke showed the 
greatest relative reductions (−43.58%, Table 3), followed 
by AMI (−39.40%, Table 2).
In the overall population without type 2 diabetes, the 
greatest relative reductions observed were for hospi-
talization for hemorrhagic stroke (−29.47%, Table  4; 
Fig.  1b), followed by hospitalization due to ischemic 
stroke (−28.92%, Table  3; Fig.  1b). When we per-
formed subgroup analyses according to gender and age 
groups (i.e., aged <65 years and ≥65 years) in Korean 
adults without type 2 diabetes, the greatest relative 
reductions among the six predefined cardiovascular 
complications were observed for hospitalizations due 
to hemorrhagic stroke for men (−28.74%, Table  4) 
Table 3 Age and  gender standardized rates of  ischemic stroke among  Korean adults according to  the presence or 
absence of diabetes (2006–2013)
In the whole analysis, P values for interaction between diabetes status and years was less than .0001 by regression models
Variables Year Change P value
2006–2007 2008–2009 2010–2011 2012–2013 Absolute change Percent change Linear trend
Ischemic stroke
 Overall population
  No. of events/10,000 in 
diabetes
188.94 157.29 135.46 119.07 −69.87 −36.98 <.0001
  95% CI 186.41–191.46 155.28–159.29 133.75–137.18 117.51–120.63
  No. of events/10,000 in 
non‑diabetes
64.72 58.25 51.29 46.00 −18.72 −28.92 <.0001
  95% CI 64.66–64.78 58.21–58.30 51.25–51.33 45.96–46.03
  RR (95% CI) 2.92 (2.88–2.96) 2.70 (2.66–2.74) 2.64 (2.60–2.68) 2.59 (2.55–2.63) <.0001
 Men
  No. of events/10,000 in 
diabetes
188.65 159.79 141.53 125.13 −63.52 −33.67 <.0001
  95% CI 184.30–193.00 156.42–163.16 138.67–144.39 122.68–127.58
  No. of events/10,000 in 
non‑diabetes
63.64 57.35 51.63 46.93 −16.71 −26.26 <.0001
  95% CI 63.52–63.75 57.25–57.44 51.55–51.70 46.86–46.99
  RR (95% CI) 2.96 (2.92–3.01) 2.79 (2.75–2.83) 2.74 (2.7–2.78) 2.67 (2.63–2.7) <.0001
 Women
  No. of events/10,000 in 
diabetes
189.2 154.96 129.82 113.43 −75.77 −40.05 <.0001
  95% CI 183.56–194.84 150.39–159.52 125.90–133.73 109.74–117.12
  No. of events/10,000 in 
non‑diabetes
65.73 59.1 50.98 45.13 −20.60 −31.34 <.0001
  95% CI 65.62–65.85 59.01–59.19 50.91–51.05 45.07–45.19
  RR (95% CI) 2.88 (2.84–2.92) 2.62 (2.59–2.66) 2.55 (2.51–2.58) 2.51 (2.48–2.55) <.0001
 Aged < 65 years
  No. of events/10,000 in 
diabetes
104.76 91.84 82.45 75 −29.76 −28.41 <.0001
  95% CI 101.91–107.61 89.24–94.43 80.20–84.71 72.91–77.09
  No. of events/10,000 in 
non‑diabetes
22.98 21.07 19.66 18.12 −4.86 −21.15 <.0001
  95% CI 22.96–23.00 21.05–21.09 19.64–19.67 18.10–18.13
  RR (95% CI) 4.56 (4.48–4.64) 4.36 (4.28–4.44) 4.19 (4.12–4.27) 4.14 (4.07–4.21) <.0001
 Aged ≥ 65 years
  No. of events/10,000 in 
diabetes
653.11 523.37 433.24 368.51 −284.6 −43.58 <.0001
  95% CI 595.24–710.98 490.38–556.36 412.47–454.00 354.72–382.30
  No. of events/10,000 in 
non‑diabetes
315.28 291.7 253.99 228.35 −86.93 −27.57 <.0001
  95% CI 312.09–318.47 288.99–294.41 251.83–256.15 226.62–230.08
  RR (95% CI) 2.07 (2.05–2.1) 1.79 (1.77–1.82) 1.71 (1.68–1.73) 1.61 (1.59–1.63) <.0001
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and adults aged <65 years (−30.68%, Table 4), as well 
as ischemic stroke for women (−34.34%, Table 3) and 
adults aged ≥65 years (−27.57%, Table 3), respectively.
Regarding PCI, we observed some mixed patterns. Com-
pared with other cardiovascular complications, all of which 
showed decreasing trends in relative reductions regardless 
of the status of diabetes as shown in Tables 1, 2, 3, 4 and 6, 
the relative statistically significant increase was observed in 
men regardless of the presence of diabetes (.17 and 13.36% 
for men with diabetes and without diabetes, respectively, 
Table  5) as well as in non-diabetic adults aged  <65  years 
(2.76%) and all adults aged ≥65 years regardless of the pres-
ence of diabetes (6.19 and 28.72% for those with diabetes 
and without diabetes, respectively, Table 5).
Table 4 Age and  gender standardized rates hemorrhagic stroke among  Korean adults according to  the presence or 
absence of diabetes (2006–2013)
In the whole analysis, P values for interaction between diabetes status and years was less than .0001 by regression models
Variables Year Change P value
2006–2007 2008–2009 2010–2011 2012–2013 Absolute change Percent change Linear trend
Hemorrhagic stroke
 Overall population
  No. of events/10,000 in 
diabetes
66.44 61.22 54.65 46.43 −20.01 −30.12 <.0001
  95% CI 65.09–67.8 60– 62.45 53.57–55.72 45.5–47.36
  No. of events/10,000 in 
non‑diabetes
35.94 32.85 29.23 25.35 −10.59 −29.47 <.0001
  95% CI 35.91–35.97 32.83–32.88 29.21–29.25 25.33–25.37
  RR (95% CI) 1.85 (1.80–1.89) 1.86 (1.82–1.91) 1.87 (1.83–1.91) 1.83 (1.79–1.87) <.0001
 Men
  No. of events/10,000 in 
diabetes
69.60 64.00 58.65 47.92 −21.68 −31.15 <.0001
  95% CI 67.48–71.73 62.04–65.96 56.96–60.33 46.57–49.27
  No. of events/10,000 in 
non‑diabetes
37.65 34.6 31.14 26.83 −10.82 −28.74 <.0001
  95% CI 37.59–37.72 34.55–34.66 31.10–31.19 26.8 –26.87
  RR (95% CI) 1.85 (1.8–1.89) 1.85 (1.81–1.89) 1.88 (1.84–1.93) 1.79 (1.75–1.83) <.0001
 Women
  No. of events/10,000 in 
diabetes
63.5 58.64 50.93 45.04 −18.46 −29.07 <.0001
  95% CI 60.28–66.71 55.78–61.51 48.38–53.47 42.73–47.35
  No. of events/10,000 in 
non‑diabetes
34.35 31.22 27.45 23.97 −10.38 −30.22 <.0001
  95% CI 34.30–34.41 31.18–31.27 27.41–27.49 23.94–24.00
  RR (95% CI) 1.85 (1.80–1.90) 1.88 (1.83–1.93) 1.86 (1.81–1.90) 1.88 (1.83–1.93) <.0001
 Aged < 65 years
  No. of events/10,000 in 
diabetes
51.91 48.43 42.66 37.41 −14.5 −27.93 <.0001
  95% CI 50.05–53.78 46.69–50.17 41.10–44.22 35.96–38.86
  No. of events/10,000 in 
non‑diabetes
23.34 20.79 18.48 16.18 −7.16 −30.68 <.0001
  95% CI 23.32–23.36 20.77–20.81 18.46–18.49 16.16–16.19
  RR (95% CI) 2.22 (2.17–2.28) 2.33 (2.27–2.39) 2.31 (2.25–2.37) 2.31 (2.25–2.37) <.0001
 Aged ≥ 65 years
  No. of events/10,000 in 
diabetes
145.8 132.03 122.85 101.88 −43.92 −30.12 <.0001
  95% CI 133.07–158.54 123.83–140.22 116.69–129.00 98.04–105.72
  No. of events/10,000 in 
non‑diabetes
106.26 103.24 94.47 82.17 −24.09 −22.67 <.0001
  95% CI 105.23–107.29 102.33–104.15 93.7–95.24 81.58–82.77
  RR (95% CI) 1.37 (1.34–1.41) 1.28 (1.25–1.31) 1.3 (1.27–1.33) 1.24 (1.21–1.27) <.0001
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Trends in relative risks of cardiovascular complications 
in subjects with diabetes
The temporal trends in the relative risks of the six pre-
defined cardiovascular complications in adults with type 
2 diabetes are also shown in Tables  1, 2, 3, 4, 5 and 6, 
as well as in Fig. 2. For hospitalizations due to ischemic 
heart disease (Table  1; Fig.  2a), the relative reductions 
were more profound in adults with type 2 diabetes than 
in those without type 2 diabetes in overall population as 
well as in subgroup analyses according to gender and age 
groups. As a results, the relative risk of events associated 
with diabetes reduced from 3.13 (95% CI 3.10–3.17) dur-
ing 2006–2007 to 2.59 (95% CI 2.56–2.62) during 2012–
2013 (Table 1; Fig. 2a). Similar patterns in the relative risk 
Table 5 Age and gender standardized rates of PCI among Korean adults according to the presence or absence of diabetes 
(2006–2013)
In the whole analysis, P values for interaction between diabetes status and years was less than .0001 by regression models
Variables Year Change P value
2006–2007 2008–2009 2010–2011 2012–2013 Absolute change Percent change Linear trend
PCI
 Overall population
  No. of events/10,000 in 
diabetes
69.52 72.12 71.58 66.93 −2.59 −3.73 <.0001
  95% CI 68.56–70.48 71.26–72.98 70.72–72.45 66.16–67.70
  No. of events/10,000 in 
non‑diabetes
16.86 18.00 18.59 18.43 1.57 9.31 <.0001
  95% CI 16.84–16.87 17.98–18.01 18.58–18.6 18.42–18.44
  RR (95% CI) 4.12 (4.03–4.22) 4.01 (3.93–4.09) 3.85 (3.78–3.92) 3.63 (3.57–3.70) <.0001
 Men
  No. of events/10,000 in 
diabetes
91.56 94.84 95.28 91.72 .16 .17 .0343
  95% CI 88.89–94.22 92.49–97.18 93.03–97.52 89.54–93.9
  No. of events/10,000 in 
non‑diabetes
23.5 25.13 26.39 26.64 3.14 13.36 <.001
  95% CI 23.46–23.55 25.09–25.17 26.35–26.42 26.60–26.68
  RR (95% CI) 3.9 (3.81–3.98) 3.77 (3.7–3.85) 3.61 (3.54–3.68) 3.44 (3.38–3.5) <.001
 Women
  No. of events/10,000 in 
diabetes
49.00 50.98 49.53 43.85 −5.15 −10.51 <.001
  95% CI 47.73–50.27 49.80–52.15 48.25–50.80 42.89–44.82
  No. of events/10,000 in 
non‑diabetes
10.67 11.36 11.33 10.79 .12 1.12 .784
  95% CI 10.65–10.69 11.34–11.38 11.31–11.35 10.77–10.80
  RR (95% CI) 4.59 (4.46–4.73) 4.49 (4.37–4.61) 4.37 (4.26–4.49) 4.06 (3.96–4.17) <.001
 Aged < 65 years
  No. of events/10,000 in 
diabetes
52.51 53.43 53.2 50.13 −2.38 −4.53 <.001
  95% CI 51.30–53.73 52.30–54.55 52.09–54.31 49.14–51.13
  No. of events/10,000 in 
non‑diabetes
9.78 10.09 10.2 10.05 .27 2.76 .002
  95% CI 9.77–9.79 10.08–10.10 10.19–10.21 10.04–10.06
 RR (95% CI) 5.37 (5.23–5.51) 5.3 (5.17–5.42) 5.22 (5.10–5.33) 4.99 (4.88–5.10) <.001
 Aged ≥ 65 years
  No. of events/10,000 in 
diabetes
130.66 146.82 148.89 138.75 8.09 6.19 .0019
  95% CI 122.64–138.69 139.54–154.11 143.04–154.74 134.53–142.97
  No. of events/10,000 in 
non‑diabetes
49.31 56.65 62.66 63.47 14.16 28.72 <.001
  95% CI 48.91–49.71 56.21–57.08 62.20–63.12 63.05–63.88
  RR (95% CI) 2.65 (2.58–2.72) 2.59 (2.54–2.65) 2.38 (2.33–2.43) 2.19 (2.14–2.23) −2.59 <.001
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of the hospitalization due to ischemic heart disease were 
observed across all subgroup analyses according to gen-
der and age groups (Table 1; Fig. 2a).
The relative risks of other cardiovascular complica-
tions also showed similar patterns, in which the rela-
tive risks of hospitalization due to AMI decreased from 
3.31 (95% CI 3.24–3.38) to 2.79 (95% CI 2.73–2.85, 
Table  2; Fig.  2b), hospitalization due to ischemic stroke 
decreased from 2.92 (95% CI 2.88–2.96) to 2.59 (95% CI 
2.55–2.63, Table 3; Fig. 2c), hospitalization due to hemor-
rhagic stroke decreased from 1.85 (95% CI 1.80–1.89) to 
1.83 (95% CI 1.79–1.87, Table 4; Fig. 2d), PCI decreased 
from 4.12 (95% CI 4.03–4.22) to 3.63 (95% CI 3.57–3.70, 
Table 5; Fig. 2e), and CABG decreased from 6.15 (95% CI 
Table 6 Age and gender standardized rates of CABG among Korean adults according to the presence or absence of dia-
betes (2006–2013)
In the whole analysis, P values for interaction between diabetes status and years was less than .0001 by regression models
Variables Year Change P value
2006–2007 2008–2009 2010–2011 2012–2013 Absolute change Percent change Linear trend
CABG
 Overall population
  No. of events/10,000 in 
diabetes
8.19 7.46 6.46 5.63 −2.56 −31.25 <.0001
  95% CI 8.10–8.28 7.40–7.53 6.38–6.54 5.56–5.70
  No. of events/10,000 in 
non‑diabetes
1.33 1.29 1.13 .976 −.35 −26.67 <.0001
  95% CI 1.33–1.332 1.291–1.293 1.131–1.133 .975–.976
  RR (95% CI) 6.15 (5.76–6.57) 5.78 (5.43–6.15) 5.71 (5.36–6.08) 5.77 (5.41–6.15) <.0001
 Men
  No. of events/10,000 in 
diabetes
11.40 10.28 8.94 8.01 −3.39 −29.74 <.0001
  95% CI 11.16–11.64 10.09–10.48 8.75–9.12 7.86–8.17
  No. of events/10,000 in 
non‑diabetes
2.02 1.94 1.67 1.462 −.56 −27.48 <.0001
  95% CI 2.013–2.02 1.94–1.947 1.667–1.672 1.46–1.464
  RR (95% CI) 5.66 (5.3–6.04) 5.29 (4.97–5.63) 5.35 (5.02–5.7) 5.48 (5.14–5.84) <.0001
 Women
  No. of events/10,000 in 
diabetes
5.196 4.838 4.159 3.411 −1.79 −34.35 <.0001
  95% CI 5.081–5.310 4.759–4.917 4.018–4.299 3.279–3.542
  No. of events/10,000 in 
non‑diabetes
.692 .685 .632 .523 −.17 −24.42 <.0001
  95% CI .691–.694 .684–.686 .631–.633 .522–.523
  RR (95% CI) 7.51 (6.79–8.30) 7.06 (6.42–7.77) 6.58 (5.97–7.25) 6.52 (5.88–7.23) <.0001
 Aged < 65 years
  No. of events/10,000 in 
diabetes
5.807 5.157 4.567 3.91 −1.90 −32.67 <.0001
  95% CI 5.709–5.906 5.079–5.235 4.467–4.667 3.825–3.995
  No. of events/10,000 in 
non‑diabetes
.727 .686 .572 .505 −.22 −30.54 <.0001
  95% CI .726–.727 .685–.686 .572–.573 .505–.506
  RR (95% CI) 7.99 (7.37–8.66) 7.52 (6.96–8.12) 7.98 (7.37–8.65) 7.74 (7.13–8.41) <.0001
 Aged ≥ 65 years
  No. of events/10,000 in 
diabetes
15.749 14.518 12.417 10.875 −4.87 −30.95 <.0001
  95% CI 14.895–16.603 14.01–15.026 12.055–12.779 10.641–11.109
  No. of events/10,000 in 
non‑diabetes
3.645 3.77 3.552 3.101 −.54 −14.92 <.0001
  95% CI 3.621–3.67 3.745–3.794 3.531–3.573 3.084–3.117
  RR (95% CI) 4.32 (4.01–4.66) 3.85 (3.59–4.13) 3.5 (3.26–3.75) 3.51 (3.26–3.77) <.0001
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5.76–6.57) to 5.77 (95% CI 5.41–6.15, Table  6; Fig.  2f ), 
respectively.
Trends in the prevalence of hypertension and dyslipidemia 
according to the status of diabetes
We analyzed the age and gender standardized prevalence 
of treated hypertension and dyslipidemia in adults with 
and without type 2 diabetes during the study period. As 
shown in Fig.  3, the increasing trend in the prevalence 
of hypertension and dyslipidemia was more profound 
in subjects without diabetes compared with those with 
diabetes (11.97 vs. 8.33% for hypertension and 48.1 vs. 
36.93% for dyslipidemia, respectively), although the abso-
lute prevalence of both comorbidities was higher in sub-
jects with diabetes compared with those without diabetes 
(Fig. 3).
Discussion
Our current analysis of nationwide whole population-
based claims data revealed a substantial relative reduc-
tion in the incidence of cardiovascular complications, 
with exception of PCI, in the Korean population between 
Fig. 1 Age and gender standardized events (per 10,000 adults) of six cardiovascular complications in populations a with diabetes, and b without 
diabetes
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2006 and 2013. Generally, in subjects with diabetes, hos-
pitalization due to AMI (Table  2) and ischemic stroke 
(Table  3) accounted for the greatest relative reduc-
tions. Reductions in the rates were smallest for PCI, 
which actually increased among men and older adults 
(Table 5). Finally, the relative decreases in all six prede-
fined cardiovascular complications were generally more 
profound in adults with diabetes than in those without 
diabetes (Tables 1, 2, 3, 4, 5 and 6), which led to signifi-
cant decrease in the relative risks of all six cardiovascu-
lar complications in subjects with diabetes over the past 
8 years (Tables 1, 2, 3, 4, 5 and 6; Fig. 2). However, peo-
ple with diabetes continued to show a two- to sixfold 
higher risk of hospitalization for major CVD events and 
Fig. 2 Relative risks of six cardiovascular complications in subjects with diabetes compared with subjects without diabetes. a Ischemic heart dis‑
ease, b acute myocardial infarction (AMI), c ischemic stroke, d hemorrhagic stroke, e percutaneous coronary intervention (PCI), and f coronary artery 
bypass and graft (CABG)
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interventions than people without diabetes (Tables  1, 2, 
3, 4, 5 and 6; Fig.  2). Our findings suggest a significant 
reduction in the rate of people affected by CVD within 
the diabetic population. However, as the number of peo-
ple with diabetes rises (Additional file  1: Table S1), the 
absolute burden of CVD will remain high in Korea, high-
lighting the urgent need for comprehensive measures in 
preventing diabetes [25]. Our study is the first to show 
the recent admission rate for major CVD events and car-
diovascular interventions in people with diabetes using a 
nationwide population claims database that covers nearly 
the entire population of Korea.
The importance of diabetes as a major cardiovascu-
lar risk factor has received considerable attention in the 
last decade [13]. Our findings of improved cardiovascu-
lar complications in the diabetic population support the 
findings of recent national survey- and registry-based 
studies in the US [11], as well as a nationwide study in 
England [26]. Numerous evidence-based interventions 
exist, ranging from glycemic and CVD risk factor control 
to early screening for diabetes complications [27]. These 
have been paralleled by population-wide improvements 
in glycemic control, CVD risk factors, and rates of several 
diabetes complications [28–30]. Indeed, favorable trends 
in the prevalence of hypertension, dyslipidemia, and cig-
arette smoking have been observed in Western countries 
[18, 19]. However, the evidence from Western popula-
tions cannot simply be extrapolated to Asian populations 
because there are ethnic differences in both the preva-
lence of cardiovascular risk factors and their association 
with diabetes [31].
In Korea, significant risk factor modifications, such 
as improved control of blood pressure and dyslipidemia 
as well as a decreased smoking rate, have also been 
observed in recent decades [17]. Although little is known 
about the secular trends in the control of hypertension 
among diabetic patients in Korea, recent data suggested 
better control of hypertension in the those population 
than in the non-diabetic population [32, 33]. Regarding 
dyslipidemia, the rates of awareness and treatment in 
diabetic patients were much higher than in non-diabetic 
individuals [34]. In line with these previous reports, we 
could identify that the increasing trend in the preva-
lence of hypertension and dyslipidemia under treatments 
was more profound in subjects without diabetes com-
pared with those with diabetes (Fig. 3). Even though the 
increased uptake of community treatments substantially 
accounted for the reduction in CVD mortality [35], these 
improvements might have led to the overall significant 
reduction in cardiovascular complications in the popula-
tion of Korean adults with diabetes compared with those 
without diabetes.
During the study period, we observed some mixed pat-
terns in the number of PCI (Table 5). The relative statisti-
cally significant increase was observed in men regardless 
of the presence of diabetes as well as in non-diabetic 
adults aged  <65  years and all adults aged  ≥65  years 
regardless of the presence of diabetes (Table  5). This 
result is in accordance with those of other studies [26, 
36], in which the PCI rate significantly increased due to 
marked advances in stent technology, such as the intro-
duction of drug-eluting stents and adjunctive pharma-
cology [26, 36]. Although CABG offers more advantages 
in terms of survival and the need for repeat revasculari-
zation for patients with severe forms of coronary artery 
disease, particularly patients with diabetes [26], the 
aforementioned technological advances in PCI might 
have contributed to the shift from CABG to PCI in sub-
jects with diabetes, as in individuals without diabetes.
When we compare the relative risk of major cardio-
vascular events and coronary interventions, the relative 
risks of hospitalization due to hemorrhagic stroke (i.e., 
less than 2.0 during the study period, Table 4; Fig. 2d) as 
Fig. 3 Age and gender standardized prevalence of hypertension and 
dyslipidemia in populations a with diabetes, and b without diabetes
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well as the decline in the relative risks of hospitalization 
due to hemorrhagic stroke (i.e., 1.85 during 2006–2007 to 
1.83 during 2012–2013, Table 4; Fig. 2d) were fairly small 
compared with other complications in individuals with 
diabetes. Diabetes is a risk factor mainly for ischemic 
stroke, though its association with hemorrhagic stroke 
remains controversial and depends on ethnicity [37]. In 
the Honolulu Heart Program, diabetes was not associated 
with an increased risk of hemorrhagic stroke in Japanese-
American men, while in the Framingham study, there 
was a 4.5-fold excess risk of this type of stroke in white 
men with diabetes [38]. This relative lack of association of 
diabetes with hemorrhagic stroke at least in Asian pop-
ulations might have resulted in the comparatively small 
relative risk, as well as the small decline of relative risk of 
hemorrhagic stroke in subjects with diabetes compared 
to those without diabetes in our analysis (Table 4).
There are several limitations to our study that need to 
be addressed. First, although the NHIS database repre-
sents the entire Korean population, one of the most criti-
cal drawbacks is the discrepancy between the diagnosis 
of individuals in real practice and that recorded in the 
claims database. However, the proportion of discrepan-
cies in diagnosis is less prominent in claims data from 
in-patient hospitalization and procedure codes [20]. This 
was the reason why we defined cardiovascular complica-
tions based on hospital discharge and coronary interven-
tion codes. Second, the operational definition of type 2 
diabetes could be problematic because we defined diabe-
tes based on the presence of both corresponding ICD-10 
codes and claims for anti-diabetic drugs. Therefore, our 
results cannot be applied to subjects with undiagnosed 
diabetes and those with diabetes who are not taking any 
diabetic drugs. Third, we could not identify those with 
cardiovascular complications prior to 2002, because the 
Korean NHIS did not maintain and manage databases 
before 2002. Thus, there remains the possibility that inci-
dent events might be recurrent events in some subjects, 
if the events had occurred prior to 2002. Fourth, we could 
not obtain the mortality rate caused by predefined cardi-
ovascular complications because the NHIS database does 
not present the cause of death [20]. Therefore, we could 
not ascertain that the reduced incidence of CVD events 
led to improved survival in subjects with and without 
diabetes. However, it is very important to investigate inci-
dence for an accurate estimation of cardiovascular risk 
factors and the evaluation of population-based preven-
tion program [39]. Finally, although our findings showed 
a substantial fall in CVD rates, we cannot attribute this 
change to one particular intervention over another. In a 
similar context, although we provided the subgroup anal-
ysis according to gender and age groups, we could not 
perform a detailed analysis according to comorbidities 
such as renal failure or obesity as well as socioeconomic 
status or region, all of which have been known to affect 
cardiovascular events and mortality in subjects with dia-
betes [40–44].
Despite the above limitations, one of the main strengths 
of our study is that we included all adults in the general 
population, allowing the study to reflect outcomes as 
they exist in the real world with minimal selection bias.
In conclusion, our findings indicate that the care and 
management of patients with diabetes have substantially 
improved in recent years in Korea and that efforts aimed 
at both primary and secondary prevention might have 
contributed to these favorable secular changes. However, 
as the number of people with diabetes rises, the absolute 
burden of CVD will continue to be high in Korea. There-
fore, these findings emphasize the continuing need for 
aggressive risk reduction in people with diabetes.
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